PFE · News · 20261114N
GLP-1 China Reimbursement Access
PFIZER INC · 2026-11-14 · Importance 44 · Surprise 42 · In source text
China added GLP-1 drugs from Pfizer and Innovent Biologics to its national health insurance scheme for type 2 diabetes patients, effective January 1. The inclusion expands access to China’s diabetic population and places the drugs in a reimbursement environment where inclusion typically leads to lower manufacturer prices. The change also intensifies competition with Novo Nordisk’s Ozempic, which is already on the list.
Key facts
- China added Pfizer's GLP-1 drugs to its national health insurance scheme for type 2 diabetes patients, effective January 1. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | China added Pfizer's GLP-1 drugs to its national health insurance scheme for type 2 diabetes patients, effective January 1. |